Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"OncoResponse","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"OncoResponse Announces Clinical Supply Agreement with Regeneron to Evaluate OR2805 in Combination with Libtayo\u00ae (cemiplimab) in Patients with Advanced Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"OncoResponse","sponsor":"CPRIT","pharmaFlowCategory":"D","amount":"$13.0 million","upfrontCash":"Undisclosed","newsHeadline":"OncoResponse Awarded $13 Million in Funding from CPRIT to Advance Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"OncoResponse","sponsor":"RiverVest Venture Partners","pharmaFlowCategory":"D","amount":"$14.0 million","upfrontCash":"Undisclosed","newsHeadline":"OncoResponse Raises $14 Million in Added Funds from Investors to Advance Cancer Immunotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2023","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"OncoResponse","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"OncoResponse Announces Initiation of Phase 1\/2 Clinical Trial of OR502, Anti-LILRB2 Antibody, in Subjects with Advanced Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by OncoResponse

    Menu

    OncoResponse

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              OncoResponse

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OncoResponse Announces Initiation of Phase 1/2 Clinical Trial of OR502, Anti-LILRB2 Antibody, in Subjects with Advanced Cancer

              Details:

              OR502 a novel, humanized anti-leukocyte immunoglobulin like receptor B2 (LILRB2) antibody. It is being evaluated for the treatment of advanced solid tumors.

              Lead Product(s): OR502,Cemiplimab

              Therapeutic Area: Oncology Product Name: OR502

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 29, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OncoResponse

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OncoResponse Awarded $13 Million in Funding from CPRIT to Advance Cancer Immunotherapy

              Details:

              The CPRIT award will support the advancement of OR502, a best-in-class anti-LILRB2 antibody that rescues innate and adaptive immune responses from LILRB2-mediated immune suppression, poised to move to IND and clinical studies.

              Lead Product(s): OR502

              Therapeutic Area: Oncology Product Name: OR502

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: CPRIT

              Deal Size: $13.0 million Upfront Cash: Undisclosed

              Deal Type: Funding May 18, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OncoResponse

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OncoResponse Raises $14 Million in Added Funds from Investors to Advance Cancer Immunotherapy

              Details:

              The investment will support the advancement of OR502, a best-in-class anti-LILRB2 antibody that rescues innate and adaptive immune responses from LILRB2-mediated immune suppression, poised to move to IND and clinical studies.

              Lead Product(s): OR502

              Therapeutic Area: Oncology Product Name: OR502

              Highest Development Status: IND Enabling Product Type: Large molecule

              Partner/Sponsor/Collaborator: RiverVest Venture Partners

              Deal Size: $14.0 million Upfront Cash: Undisclosed

              Deal Type: Financing May 18, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              OncoResponse

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              OncoResponse Announces Clinical Supply Agreement with Regeneron to Evaluate OR2805 in Combination with Libtayo® (cemiplimab) in Patients with Advanced Cancer

              Details:

              The supply agreement will support the evaluation of Libtayo in combination with OR2805, a fully human monoclonal antibody identified from an elite cancer responder using OncoResponse’s proprietary B-cell discovery platform.

              Lead Product(s): OR2805,Cemiplimab

              Therapeutic Area: Oncology Product Name: OR2805

              Highest Development Status: Preclinical Product Type: Large molecule

              Partner/Sponsor/Collaborator: Regeneron Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement September 07, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY